About the Company
eyenovia, inc. (nasdaq: eyen) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, presbyopia, mydriasis and other eye diseases.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $EYEN News
Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates
Eyenovia, Inc. (EYEN) delivered earnings and revenue surprises of -5.88% and 99.40%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
Announced FDA approval of clobetasol propionate ophthalmic suspension 0.05% for post-operative pain and inflammation following ocular ...
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th
Eyenovia is currently focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce ...
Earnings Preview For Eyenovia
Analysts estimate that Eyenovia will report an earnings per share (EPS) of $-0.17. Eyenovia bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide ...
Eyenovia Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Eyenovia, Formosa Win FDA Approval for Anti-Inflammatory Eye Drops
The regulator has approved Eyenovia and Formosa’s ophthalmic clobetasol propionate solution to ease eye inflammation and pain ...
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion ...
Beyond Cataract Surgery: Analyst Highlights Broader Market Potential For Eyenovia/Formosa's Steroid For Post-Eye Surgery Pain, Inflammation
Eyenovia Inc (NASDAQ:EYEN) is Formosa Pharmaceuticals’ U.S. commercialization partner. In August 2023, Formosa ...
Eyenovia, Inc. (EYEN)
*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Loading the latest forecasts...